Stock EQ EQUILLIUM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Equillium, Inc.

Equities

EQ

US29446K1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
0.801 USD -10.69% Intraday chart for Equillium, Inc. -46.60% +10.79%
Jun. 04 Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101 CI
May. 14 Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Equillium Reports Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
BU
Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101
CI
Equillium to Present at the Jefferies Global Healthcare Conference
BU
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
BU
Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
CI
Earnings Flash (EQ) EQUILLIUM Reports Q1 Revenue $10.7M
MT
Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.
CI
Equillium, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
BU
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
BU
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating
MT
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
BU
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis
CI
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup
DJ
Equillium Swings to Q4 Loss As Revenue Falls
MT
Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.
CI
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EQ Stock
  4. News Equillium, Inc.